Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Hodgkin Disease 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 119fludarabine phosphate 97Cytarabine 86fludarabine 74Methotrexate 70Rituximab 68Busulfan 56Whole-Body Irradiation 48Filgrastim 48Tacrolimus 43Mycophenolic Acid 43Antilymphocyte Serum 40Etoposide 37Peripheral Blood Stem Cell Transplantation 36Granulocyte Colony-Stimulating Factor 35Melphalan 34Vincristine 33Alemtuzumab 33Cyclosporine 32Clofarabine 30Azacitidine 30Dexamethasone 29Imatinib Mesylate 26thymoglobulin 25Doxorubicin 23sargramostim 22Lenalidomide 22Methylprednisolone 20Stem Cell Transplantation 19Daunorubicin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT00671658 2020-12-03

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
220 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡